Ipsen SA Total Liabilities
Ipsen SA total liabilities. Based on the latest financial reports, Ipsen SA (IPN) has total liabilities worth €2.60 Billion EUR (≈ $3.04 Billion USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Ipsen SA liquidity resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Ipsen SA (2002–2024)
Total liabilities of Ipsen SA from 2002 to 2024. This chart illustrates how Ipsen SA's total liabilities have evolved over time, based on quarterly financial data. Explore investment intensity of Ipsen SA to see how much of total assets are deployed in long-term investments.
Ipsen SA Competitors by Total Liabilities
The table below lists competitors of Ipsen SA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Industrial Bank Of Korea
KO:024110
|
Korea | ₩463.84 Trillion |
|
RAKUTEN GROUP SPONS.ADR 1
F:RAKA
|
Germany | €27.45 Trillion |
|
APA Group
AU:APA
|
Australia | AU$17.52 Billion |
|
Klepierre SA
PA:LI
|
France | €10.70 Billion |
|
Ambuja Cements Limited
NSE:AMBUJACEM
|
India | Rs177.60 Billion |
|
Sichuan Kelun Pharmaceutical Co Ltd
SHE:002422
|
China | CN¥11.66 Billion |
|
Insurance Australia Group Limited
F:NRM
|
Germany | €18.52 Billion |
|
Hensoldt AG
F:HAG
|
Germany | €4.72 Billion |
Liability Composition Analysis (2002–2024)
This chart breaks down Ipsen SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see IPN total asset value.
Liquidity & Leverage Metrics
Ipsen SA Total Liabilities Ratios Explained
Ipsen SA total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.98 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 1.02 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.61 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.38 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Ipsen SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Ipsen SA (2002–2024)
The table below shows the annual total liabilities of Ipsen SA from 2002 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €2.26 Billion ≈ $2.64 Billion |
-9.68% |
| 2023-12-31 | €2.50 Billion ≈ $2.92 Billion |
+10.03% |
| 2022-12-31 | €2.27 Billion ≈ $2.66 Billion |
+0.82% |
| 2021-12-31 | €2.25 Billion ≈ $2.63 Billion |
+3.38% |
| 2020-12-31 | €2.18 Billion ≈ $2.55 Billion |
-14.68% |
| 2019-12-31 | €2.55 Billion ≈ $2.99 Billion |
+66.49% |
| 2018-12-31 | €1.53 Billion ≈ $1.79 Billion |
-0.14% |
| 2017-12-31 | €1.54 Billion ≈ $1.80 Billion |
+44.74% |
| 2016-12-31 | €1.06 Billion ≈ $1.24 Billion |
+48.98% |
| 2015-12-31 | €712.40 Million ≈ $832.87 Million |
+10.38% |
| 2014-12-31 | €645.40 Million ≈ $754.54 Million |
+9.09% |
| 2013-12-31 | €591.60 Million ≈ $691.64 Million |
-6.81% |
| 2012-12-31 | €634.84 Million ≈ $742.19 Million |
+2.73% |
| 2011-12-31 | €617.97 Million ≈ $722.47 Million |
+3.17% |
| 2010-12-31 | €598.96 Million ≈ $700.25 Million |
+1.09% |
| 2009-12-31 | €592.52 Million ≈ $692.72 Million |
-15.52% |
| 2008-12-31 | €701.36 Million ≈ $819.96 Million |
+34.41% |
| 2007-12-31 | €521.81 Million ≈ $610.05 Million |
+7.29% |
| 2006-12-31 | €486.37 Million ≈ $568.62 Million |
+51.32% |
| 2005-12-31 | €321.41 Million ≈ $375.76 Million |
-23.83% |
| 2004-12-31 | €421.98 Million ≈ $493.34 Million |
+19.12% |
| 2003-12-31 | €354.24 Million ≈ $414.15 Million |
-18.45% |
| 2002-12-31 | €434.38 Million ≈ $507.83 Million |
-- |
About Ipsen SA
Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide. Its oncology products include Somatuline for the treatment of neuroendocrine tumors and acromegaly; Cabometyx, a tyrosine kinase inhibitor to treat second line pancreatic and extra-pancreatic neuroendocrine tumors; Onivyde, an irinotecan liposome injec… Read more